OBJECTIVE: To evaluate the efficacy and safety of Qiangli Dingxuan tablets（ capsules） combined with betastine in the treatment of vertigo based on evidence-based pharmacy. METHODS: Embase

PubMed

the Cochrane Library

Wanfang database

CNKI and CBM were retrieved to collect the randomized controlled trial of Qiangli Dingxuan tablets（ capsules） combined with betastine in the treatment of vertigo[the study group was given Qiangli Dingxuan tablets（ capsules） combined with betastine

while the control group received betastine alone]. The retrieval time was from the establishment of the database to Jun. 2021. After two researchers extracted data

selected literature and evaluated the risk of bias in the included literature

Meta-analysis was performed by using RevMan 5. 4 software.RESULTS: Totally 11 randomized controlled trials were collected

including 956 patients（ 478 cases in the experimental group and 478 cases in the control group）. Meta-analysis results showed that the total effective rate（ OR = 5. 19

95%CI= 3. 33-8. 10

P<0. 000 01） and significant rate（ OR = 2. 09

95%CI= 1. 57-2. 78

P<0. 000 01）

recovery rate（ OR = 3. 75

95%CI = 1. 86-7. 55

P = 0. 000 2）

vertigo symptom score（ MD =-4. 40

95% CI =-4. 82--3. 98

P<0. 000 01）

dizziness handicap inventory score（ MD =-10. 57

95% CI =-11. 92--9. 22

P < 0. 000 01）

plasma viscosity（ MD =-0. 25

95%CI =-0. 32--0. 17

P<0. 000 01）

left vertebral artery blood flow velocity（ MD =4. 56

95%CI = 3. 38-5. 74

P<0. 000 01）

right vertebral artery blood flow velocity（ MD = 4. 37

95%CI = 3. 85-4. 90

P<0. 000 01）

basilar artery blood flow velocity（ MD = 3. 49

95%CI = 2. 68-4. 31

P<0. 000 01）

endothelin-1 level（ MD=-29. 72

95%CI=-31. 29--28. 15

P<0. 000 01）

calcitonin gene-related peptide level（ MD= 6. 21

95%CI =5. 43-6. 99

P< 0. 000 01） and ratio of endothelin 1/calcitonin gene-related peptide（ OR =-2. 01

95% CI =-2. 38--1. 63

P<0. 000 01） in the study group were significantly better than those in the control group

the differences were statistically significant. There was no significant difference in the incidence of adverse drug reactions between two groups（ OR = 0. 59

95% CI = 0. 14-2. 53

P = 0. 47 > 0. 05）. CONCLUSIONS: Existing evidence shows that Qiangli Dingxuan tablets（ capsules） combined with betastine are safe and effective in the treatment of vertigo

which has significant advantages over betahistine alone. Due to the limitations of the quantity and quality of the included literature

the conclusions need to be verified by more high-quality randomized controlled trials in the future.